Leukocyte glucose index as a novel biomarker for COVID-19 severity.

ABSTRACT: The severity of coronavirus disease 2019 (COVID-19) quickly progresses with unfavorable outcomes due to the host immune response and metabolism alteration. Hence, we hypothesized that leukocyte glucose index (LGI) is a biomarker for severe COVID-19. This study involved 109 patients and the usefulness of LGI was evaluated and compared with other risk factors to predict COVID 19 severity. LGI was identified as an independent risk factor (odds ratio [OR] = 1.727, 95% confidence interval [CI]: 1.026-3.048, P = 0.041), with an area under the curve (AUC) of 0.749 (95% CI: 0.642-0.857, P < 0.0001). Interestingly, LGI was a potential risk factor (OR = 2.694, 95% CI: 1.575-5.283, P_corrected < 0.05) for severe COVID-19 in female but not in male patients. In addition, LGI proved to be a st

SUBMITTER: Ramos-Hernandez WM 

PROVIDER: S-EPMC9438363 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature